Protalix BioTherapeutics, Inc. (NYSE American: PLX), an Israel-based biopharmaceutical company involved in the development, production and commercialisation of recombinant therapeutic proteins produced by its proprietary ProCellEx(R) plant cell-based protein expression system, announced on Thursday that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, 26 June 2024 at 08:30 Eastern Daylight Time (EDT).

The investor day will feature presentations by Ales Linhart, DSc, FESC (Charles University, Prague), who will discuss the treatment landscape for Fabry disease and perspectives on Elfabrio(R) (pegunigalsidase alfa), a plant cell-expressed PEGylated recombinant a-Galactosidase-A enzyme approved for adult patients with Fabry disease, and Naomi Schlesinger, MD (University of Utah), who will discuss the current treatment landscape for uncontrolled gout and top-line results from the First-in-Human Phase I single ascending dose clinical trial of PRX-115, a plant cell-expressed recombinant PEGylated uricase.

In addition, the event will include a corporate overview and strategy presentation by Dror Bashan, Protalix's president and chief executive officer. A live question and answer session will follow the formal presentations. To register for the event visit https://protalix.com/ .